PROS1 and neoplasm: In line with these observations, higher immunoreactivity scores were found in patients without a biochemical (PSA) tumor recurrence (statistically significant in benign samples, close to significance in all samples; Fig. 5E), and in patients with a lower serum PSA (≤4 vs. > 4 ng/ml; Fig. 5F).